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A B S T R A C T
Alfaxalone-2-hydroxpropyl-β-cyclodextrin (alfaxalone-HPCD) was ﬁrst marketed for veterinary use in Aus-
tralia in 2001 and has since progressively became available throughout the world, including the USA,
where in 2012 Food and Drug Administration (FDA) registration was granted. Despite the growing body
of published works and increasing global availability of alfaxalone-HPCD, the accumulating evidence for
its use in cats has not been thoroughly reviewed. The purpose of this review is: (1) to detail the phar-
macokinetic properties of alfaxalone-HPCD in cats; (2) to assess the pharmacodynamic properties of
alfaxalone-HPCD, including its cardiovascular, respiratory, central nervous system, neuromuscular, hepatic,
renal, haematological, blood-biochemical, analgesic and endocrine effects; and (3) to consider the clin-
ical application of alfaxalone-HPCD for sedation, induction and maintenance of anaesthesia in cats. Based
on the published literature, alfaxalone-HPCD provides a good alternative to the existing intravenous an-
aesthetic options for healthy cats.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Alfaxalone (3α-hydroxy-5α-pregnane-11,20-dione) is a synthetic
neuroactive steroid, which enhances the interaction of the inhib-
itory neurotransmitter gamma (γ) aminobutyric acid type A (GABA)A
receptor complex to produce anaesthesia and muscle relaxation
(Harrison and Simmonds, 1984; Albertson, 1992). Alfaxalone was
ﬁrstmarketed as an anaesthetic in 1971 co-formulatedwith a similar,
less potent, neuroactive steroid, alfadolone (3α,21-dihydroxy-5α-
pregnane-11,20-dione), and dissolved in 20%W/V polyethoxylated
castor oil surfactant (Cremophor EL, BASF Fine Chemicals) (Child
et al., 1971).
This three-in-one formulation (CT 1341), which was marketed
for both human (Althesin, GlaxoSmithKline) and veterinary (Saffan,
GlaxoSmithKline) administration, caused severe side effects in nu-
merous species. In cats the predominant adverse effects were
hyperaemia and oedema of the pinnae and forepaws, urticaria and
skin erythema (Dodman, 1980). CT 1341 caused an unacceptably
high incidence of anaphylactoid reactions in dogs and humans, which
subsequently saw Althesin withdrawn from human clinical prac-
tice in 1984 (Watt, 1975; Abraham and Davis, 2005). These adverse
effects were mainly attributed to the Cremophor EL vehicle and,
while Saffan continued to be available for veterinary use until 2002,
it was contraindicated for use in dogs.
In 1999, a lyophilised powder of alfaxalone and cyclodextrin re-
quiring reconstitution (Alfaxan-CD) was released; however, this
product was only registered for use in cats. In 2001 a clear colourless,
surfactant-free, aqueous formulation of 1% W/V alfaxalone dis-
solved with 2-hydroxpropyl-β-cyclodextrin (HPCD) was released for
veterinary use in Australia (Alfaxan-CD RTU, Jurox) (Brewster et al.,
1989; Estes et al., 1990); this new formulation has not demon-
strated the side-effects observed with the previous (CT 1341)
preparation (APVMA, 2010).
Cyclodextrins are ring-shaped chains of sugar molecules ar-
ranged so that their hydrophilic domains face outwards and their
lipophilicdomains face inwards. Theyare soluble inwater andprovide,
within their hydrophobic core, space for interaction with hydro-
phobic molecules, such as steroids. The 1:1molar HPCD:alfaxalone
aggregate therefore behaves as one molecule to form an isotropic
solution in water. This aggregate must dissociate in vivo, allowing
the alfaxalone to obtain pseudo-equilibrium between its free
(unbound) concentration and those molecules that are bound to
plasma proteins and cellmembranes (Brewster et al., 1989). The use
of cyclodextrins in pharmaceutical formulations has been re-
viewed by Davis and Brewster (2004).
Although the newest formulation of alfaxalone (alfaxalone-
HPCD) has been made available in many countries, including
Australia, New Zealand, South Africa, Thailand, Canada and numer-
ous European countries, the accumulating evidence for its use in
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cats has not been thoroughly reviewed. In September 2012,
alfaxalone-HPCD was approved by the USA Food and Drug Admin-
istration (FDA)1 for induction andmaintenance of anaesthesia in dogs
and cats in the United States, although its market release was delayed
by the Drug Enforcement Administration’s (DEA)2 process for sched-
uling. Alfaxalone-HPCD provides an alternative in the face of
anaesthesia drug shortages (i.e. propofol, thiopental).
The aim of this article is to review the pharmacology of alfaxalone
and the clinical application of the HPBC solubilised formulation in
the cat. This review was compiled from available original and ret-
rospective studies, reviews, texts, forum proceedings and recent
research in both the human and veterinary medical ﬁelds. Articles
were retrieved with a combination of search engines including but
not limited to PubMed, Thomas Reuters Web of Knowledge, Com-
monwealth Agricultural Bureau (CAB) Abstracts, and Ovid Medline.
Relevant articles retrieved were reviewed and, where appropriate,
their reference citations were searched for additional pertinent ar-
ticles. Attempts were made to assess human and animal studies for
relevance pertaining to the clinical application of alfaxalone in the
cat and to make recommendations in accordance with the prin-
ciples of evidence-based medicine. The resulting relative scarcity
of peer reviewed literature investigating alfaxalone in the cat is worth
noting. A total of three pharmacological studies, eight clinical studies,
one case report and two conference proceedings were found in the
literature to date.
Mechanism of anaesthetic effect
The primary mechanism of anaesthetic action of alfaxalone is
attributed to positive allosteric modulation of the GABAA receptor,
a ligand-gated chloride ion (Cl−) channel receptor for the neu-
rotransmitter GABA, which universally inhibits neuronal excitability
(Harrison and Simmonds, 1984; Albertson, 1992). Alfaxalone di-
rectly binds to GABAA receptors, potentiating the effects of
endogenous GABA, causing movement of Cl− into the cell,
hyperpolarisation of the neuron and inhibition of action potential
propagation (Lambert et al., 2003). Investigations have also re-
vealed a dual mechanism of action of alfaxalone. At low
concentration, alfaxalone allosterically modulates the amplitude of
GABA-induced ion currents, whereas, at higher concentrations,
alfaxalone exerts an agonist effect, similar to barbiturates (Cottrell
et al., 1987; Paul and Purdy, 1992; Lambert et al., 1995). The GABAA
receptor is a pentameric transmembrane ion channel at which phar-
macological properties of interacting drugs are determined by both
the receptor subunit composition and by drug subunit selectivity.
Within the central nervous system (CNS), neurones express nu-
merous GABAA receptor subunit isoforms (e.g. α1–α6, β1–β3, γ1–γ3,
δ, ε, θ, π, ρ1–ρ3) which determine the receptor’s agonist aﬃnity,
chance of opening, conductance and other pharmacological prop-
erties (Lambert et al., 2003; Olsen and Sieghart, 2008). The variability
in pharmacological properties of drugs that act at the GABAA re-
ceptor is due to variation in drug speciﬁcity for a particular subunit.
The receptor subunit speciﬁcity for binding of alfaxalone has been
evaluated in human recombinant GABAA receptors, and this work
demonstrated that alfaxalone acts best as a positive allosteric mod-
ulator on the α1β1γ2L receptor isoform (Maitra and Reynolds, 1998).
Pharmacokinetics of alfaxalone
The pharmacokinetics of alfaxalone in cats has been investi-
gated in one study involving eight cats and was found to be non-
linear (Whittem et al., 2008). When the pharmacokinetic parameters
for a drug (e.g. clearance and volume of distribution) are dose-
independent, they are said to be ‘linear’. This is a characteristic of
ﬁrst order pharmacokinetics. For drugs with linear pharmacoki-
netics, as the dose is increased, the plasma concentration and the
area under the plasma concentration–time curve (AUC) increases
in proportion to the change in dose. Linear pharmacokinetics are
usually maintained when the mechanisms of a drug’s clearance do
not approach a maximum (i.e. they do not saturate) at concentra-
tions usually achieved in vivo. However, clearance mechanisms
become saturated for some drugs or the drug’s pharmacodynamic
effects may alter the drug’s own distribution or clearance. For these
drugs the pharmacokinetic parameters, such as clearance or volume
of distribution may vary depending on the administered dose, or
may vary as a function of time.
The pharmacokinetic properties of alfaxalone in cats have been
demonstrated to be nonlinear. In nonlinear pharmacokinetics, the
drug’s effects and persistence are not predictable at different doses
and the variability between individuals may be greater than ex-
pected for drugs with linear pharmacokinetic behaviour. For a single
5 mg/kg IV dose of alfaxalone, the volume of distribution was 1.8 L/
kg; the mean terminal plasma elimination half-life (t1/2) was
approximately 45 min; and the mean plasma clearance was
25.1 ± 7.6 mL/kg/min, which represented approximately 5–10% of
cardiac output (Whittem et al., 2008). Although the effective plasma
concentration for this study was not measured, the mean of the
‘average steady state’ concentration of alfaxalone in the plasma was
2.8 ± 1.3 mg/L (Whittem et al., 2008). The authors concluded that,
at clinical dose rates, neither alfaxalone nor its effect accumulated
to a clinically relevant extent.
This large clearance of alfaxalone is suggestive of rapid meta-
bolic clearance of the parent moiety (Whittem et al., 2008). Rapid
hepatic metabolic clearance by the liver has been identiﬁed in
other species as a likely mechanism of recovery from alfaxalone
anaesthesia (Sear and McGivan, 1981). Renal, pulmonary and, po-
tentially, cerebral metabolism are also speculated to be involved
in the elimination of this drug (Holly et al., 1981; Nicholas et al.,
1981; Sear, 1996; Celotti et al., 1997; Hiroi et al., 2001; Ferre et al.,
2006). Studies in humans and rats have demonstrated that me-
tabolites of alfaxalone are primarily excreted in the urine, with a
small amount likely to be excreted in the bile (Strunin et al., 1977;
Sear, 1996). Although the exact metabolic clearance and excretion
mechanisms are unknown in cats, the alfaxalone metabolites pro-
duced are similar to those of humans and rats, allowing for the
extrapolation that renal elimination is probably also important in
this species (Warne, 2013).
Overdose and toxicity of alfaxalone
The therapeutic index is the ratio of the dose of the drug nec-
essary to induce death in 50% of the animals to which the drug is
administered (LD50) relative to the dose of drug necessary to induce
the desired effect in 50% of the animals to which it is adminis-
tered (ED50). In cats, the therapeutic index for alfaxalone has not
been established; however, in mice and rats, the therapeutic index
for Althesin is 30.4 and 28.7 respectively (Davis and Pearce, 1972;
Hogskilde et al., 1987). The higher the therapeutic index, the safer
the drug is considered to be. However the therapeutic index does
not take into consideration the gradient of the concentration–
response curve. A drug with a reasonable therapeutic index, but a
low gradient, may have an effect in 90% of the animals to which it
is administered (ED90) close to the LD50, decreasing the safety margin
1 See: New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor’s
Name; Change of Sponsor’s Address; Alfaxalone; Ivermectin and Clorsulon; Narasin;
Triptorelin. From the Federal Register Online via the Government Printing Oﬃce [FR
Doc No: 2012-N-0002] 77, pp. 64715–64718. http://www.gpo.gov/fdsys/pkg/
FR-2012-10-23/html/2012-25989.htm (accessed 15 April 2014).
2 Schedules of Controlled Substances: Placement of Alfaxalone into Schedule IV.
From the Federal Register Online via the Government Printing Oﬃce [FR Doc No:
2013-06651] 78, pp. 17895–17900. http://www.gpo.gov/fdsys/pkg/FR-2013-03-25/
html/2013-06651.htm (accessed 15 April 2014).
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of the drug. Therefore, the therapeutic index is not always useful
as a measure of a drug’s clinical safety.
The manufacturer of alfaxalone reports acute tolerance of over-
dose of up to ﬁve times in the cat (up to 25mg/kg IV); however 1/8
cats died suddenly following administration of a supraclinical dose
(25 mg/kg IV) (Whittem et al., 2008). Gross pathological ﬁndings
of this cat at postmortem examination revealed possible myocardial
thickening of the left ventricle (7.2 mm) compared with the right
ventricle (1.3 mm), although the heart weight was normal.
Pharmacodynamics
A summary of the pharmacodynamic effects of alfaxalone in the
cat is provided in Table 1.
Cardiovascular effects
There have been few studies evaluating the cardiovascular effects
of alfaxalone-HPCD in cats (Heit et al., 2004; Whittem et al., 2008;
Muir et al., 2009; Taboada and Murison, 2010; Ramoo et al., 2013).
Alfaxalone-HPCD induces a dose-dependent decrease in heart rate
(HR), cardiac output (CO) and arterial blood pressure following IV
administration in cats (Whittem et al., 2008; Muir et al., 2009).
These effects support the titration of this anaesthetic agent when-
ever administered intravenously. At a clinically relevant dose
(5 mg/kg IV) Muir et al. (2009) reported that alfaxalone-HPCD
without concomitant medications produced mild vasodilatory
changes (decreased systemic vascular resistance) and negligible
changes in HR (decreased) resulting in a minimal decrease in CO.
At supraclinical doses (15 and 50 mg/kg IV), these cardiovascular
parameters were signiﬁcantly decreased relative to pre-induction
values (Muir et al., 2009).
A decrease in systolic arterial blood pressure (SBP) and HR was
reported byWhittem et al. (2008), and Taboada andMurison (2010),
following induction of anaesthesia at clinically relevant doses (5 and
4.7 mg/kg IV, respectively). In the study by Whittem et al. (2008),
no confounding drugs were administered prior to anaesthesia;
however, in the study by Taboada andMurison (2010), cats received
Table 1
Summary of the pharmacodynamic effects of alfaxalone in cats.
Dose summary and effects Comments References
Dosage Induction: 1–3 mg/kg IV (premedicated) Zaki et al., 2009
Beths et al., 2014
Grubb et al., 2013
4–5 mg/kg IV (unpremedicated)
10 mg/kg IM IM route not recommended due to the large volume
required and prolonged recoveries with excitation
Sedation: 2–3 mg/kg SC/IM Eﬃcacious when given IM; does not cause tissue irritation;
however, large volume required (0.2–0.3 mL/kg)
Ramoo et al., 2013
TIVA: 24–250 μg/kg/min IV Adjunctive analgesic/anaesthetic agents permit dose
reduction
Beths et al., 2014
Vettorato, 2013
Cardiovascular Dose-dependent decrease in HR, CO, MAP and SVR Cardiovascular effects are well tolerated in healthy cats Whittem et al., 2008
Muir et al., 2009
Respiratory Dose-dependent decrease in RR and MV similar to
propofol
Taboada and Murison, 2010
Dose-dependent increase in PIA Decreased frequency of PIA when administered slowly to
effect
Muir et al., 2009
Taboada and Murison, 2010
Beths et al., 2014
Central nervous
system
Dose-dependent decrease in CBF, CMRO2 and ICP CNS effects of alfaxalone-HPCD extrapolated from CT 1341
ﬁndings
Baldy-Moulinier,
Besset-Lehmann, Passouant
1975
Baldy-Moulinier and
Besset-Lehmann, 1975
Potential clinical application for neuroanaesthesia Baldy-Moulinier and
Besset-Lehmann, 1975
Neuromuscular A centrally positioned eye is more likely to be
maintained during induction compared with
propofol
Eye position is unlikely to be a reliable indicator of
anaesthetic depth in cats induced with alfaxalone-HPCD
Herbert and Murison, 2013
Suitable for evaluation of laryngeal function Nelissen et al., 2012
Hepatic and renal No adverse effect reported Whittem et al., 2008
Metabolism/
excretion
Metabolised via phase I and II hepatic metabolism May be more advantageous over propofol for prolonged
infusion. It is speculated that alfaxalone-HPCD is less likely
to accumulate
Warne, 2013
Metabolites primarily excreted in the urine Strunin et al., 1977
Sear, 1996
Haematology and
biochemistry
No changes reported Heinz body formation has not been reported with
alfaxalone-HPCD
Whittem et al., 2008
Analgesia Not analgesic Adjunctive analgesia required for painful procedures Winter et al., 2003
Murison and Taboada, 2010
Endocrine Does not decrease testosterone levels in male
domestic cats and cheetahs
Unlike thiopentone and ketamine anaesthesia (unknown
for propofol)
Wildt et al., 1984
Johnstone and Bancroft, 1988
Endocrine effects of alfaxalone-HPCD extrapolated from CT
1341 ﬁndings
The effects of alfaxalone-HPCD on adrenal suppression
have not been evaluated
Induction/recovery Smooth induction and recovery; however greater
incidence of trembling and paddling in recovery
compared with propofol
Quality of recovery improves with sedation Zaki et al., 2009
Mathis et al., 2012
Recovery dependent on hepatic metabolism Hepatic insuﬃciency may prolong recovery Whittem et al., 2008
TIVA, total intravenous anaesthesia; HR, heart rate; CO, cardiac output; MAP, mean arterial blood pressure; SVR, systemic vascular resistance; RR, respiratory rate; MV, minute
volume; PIA, post-induction apnoea; CBF, cerebral blood ﬂow; CMRO2, cerebral metabolic rate of oxygen; ICP, intracranial pressure.
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acepromazine (0.05mg/kg IM) andmeloxicam (0.3mg/kg SC). While
the administration of these drugs (primarily acepromazine) could
have partially contributed to these cardiovascular ﬁndings, the extent
and timing of the pharmacodynamic effects more closely resemble
the pharmacokinetics of alfaxalone rather than acepromazine. The
lowest mean arterial blood pressures (Taboada and Murison, 2010,
50–60 mmHg; Whittem et al., 2008, 70–90 mmHg) occurred at the
ﬁrst reported post-induction measurement (5 min post-induction)
(Whittem et al., 2008; Taboada and Murison, 2010). In contrast,
clinically relevant anaesthetic induction doses of the former CT 1341
formulation produced transient tachycardia combined with a
short-lasting fall in mean arterial blood pressure (MAP) during and
just after rapid induction of anaesthesia with clinically relevant doses
of CT 1341, followed 2.5–5 min after the start of injection by a
decrease in heart rate and persisting fall in MAP (Child et al., 1972).
The fact that this study reported tachycardia and hypotension
associated with induction of anaesthesia occurring within 2.5–5min
after injection, suggests that, in their studies, Muir et al. (2009),
Taboada and Murison (2010) and Whittem et al. (2008) may have
failed to observe the full extent of any post-induction decrease in
arterial blood pressure, since recordings were not evaluated during
this time period.
The increase in HR observed by Child et al. (1972) may be due
to the rapid speed of induction (10–25 s) and was likely to have oc-
curred in response to the associated post-induction hypotension.
It is possible that, with rapid induction, the subsequent hypoten-
sion occurs sooner than if induction had occurred more slowly,
allowing a brief baroreceptor response, prior to the onset of CNS
drug concentrations, which in turn ablate the baroreceptor re-
sponse. Although the baseline HR of the subjects was high (mean
HRs were 193–214 beats per min), with increasing alfaxalone-
HPCD induction doses (administered over 1min), Muir et al. (2009)
reported a dose-dependent decrease in HR.
The decrease in CO reported following induction of anaesthesia
with alfaxalone-HPCD is likely due to a decrease in HR and stroke
volume (SV). SV is determined by preload, afterload and myocar-
dial contractility. Since preload and afterload remained relatively
unchanged (indicated by mean right atrial and pulmonary arterial
pressures, respectively), the most signiﬁcant contributor to the de-
crease in SV must be reduced contractility (Muir et al., 2009). This
is supported by the dose-dependent decrease in rate-pressure product
(RPP) following administration of alfaxalone-HPCD (Muir et al., 2009).
Rate-pressure product (HR × SBP; beats mmHg/min-1) is an index of
myocardial oxygen consumption and contractility.
In a study involving eight healthy adult cats, a clinically rele-
vant anaesthetic induction dose of alfaxalone-HPCD (5 mg/kg IV)
producedminimal decreases in RPP and CO relative to pre-induction
values (Muir et al., 2009). At supraclinical doses of alfaxalone-
HPCD (15 and 50 mg/kg IV), the same study reported a signiﬁcant
decrease in RPP, CO and systemic vascular resistance (SVR), sug-
gestive of negative inotropic effects, decreased SV and vasodilatory
effects. It is hypothesised that at these high doses, alfaxalone-
HPCD exerts both centrally mediated and direct cardiac depressive
effects. Systemic vascular resistance was maintained at clinically rel-
evant doses of alfaxalone-HPCD (Muir et al., 2009). It must be noted
that the methodology employed by Muir et al. (2009) to calculate
RPP using MAP (i.e. MAP × HR) rather than SBP (i.e. SBP × HR) de-
parted from the standard recognised formula.
Alfaxalone-HPCD has demonstrated some cardiovascular de-
pression at clinically relevant doses in healthy cats (Whittem et al.,
2008; Muir et al., 2009; Taboada and Murison, 2010). There is
only one published study that compares the cardiovascular
effects of alfaxalone and propofol (Taboada and Murison, 2010).
This study found no signiﬁcant differences in cardiovascular de-
pression in cats when anaesthesia was induced using alfaxalone-
HPCD compared with propofol. It is important to recognise that,
although alfaxalone-HPCD has demonstrated minimal cardiovas-
cular depression at clinically relevant doses, appropriate care should
be taken when administering alfaxalone-HPCD to cats with cardio-
vascular compromise, since the depressive effects have not been
investigated in this cohort and may be more signiﬁcant than ﬁnd-
ings reported in healthy cats.
Respiratory effects
Alfaxalone-HPCD induces a dose-dependent decrease in respi-
ratory rate and minute volume similar to propofol (Taboada and
Murison, 2010). Several studies have not observed post-induction
apnoea (PIA) when clinically relevant doses of alfaxalone-HPCDwere
administered IV over approximately 60 s (Whittem et al., 2008;
Taboada andMurison, 2010; Beths et al., 2014). In addition, one study
did not observe any PIA in eight cats administered a supraclinical
dose (25 mg/kg IV over 60 s) of alfaxalone-HPCD (Whittem et al.,
2008). Post-induction apnoea was deﬁned byWhittem et al. (2008)
and Beths et al. (2014) as an absence of spontaneous ventilation for
a period >30 s and by Taboada and Murison (2010), as >60 s. In con-
trast, Zaki et al. (2009) observed a PIA of 80 s in one of 22
unpremedicated cats administered alfaxalone-HPCD 1%W/V (2.7–
5.8 mg/kg IV over 60–90 s until endotracheal intubation was
achieved). In the same study, there were no reports of PIA of du-
ration greater than 15 s in premedicated cats (0.03 mg/kg
acepromazine and 0.3 mg/kg butorphanol SC) given 1% alfaxalone-
HPCD or 1% alfaxalone-HPCDW/V diluted with sterile water to 0.5%
W/V (1.7–4.7mg/kg IV administered over 60–90 s). Muir et al. (2009),
deﬁning apnoea as no physical evidence of breathing for a period
of 20 s, observed a dose-dependent increase in the incidence of PIA,
reporting 12.5, 25.0 and 100.0% in unpremedicated cats inducedwith
alfaxalone-HPCD administered over 60 s at doses of 5.0, 15.0 and
50.0 mg/kg IV, respectively. A decrease in the frequency of PIA has
been reportedwhen alfaxalone-HPCD is administered slowly to effect
(Taboada and Murison, 2010; Beths et al., 2014).
Effects on cerebral haemodynamics and metabolism
The effects of alfaxalone-HPCD on cerebral haemodynamics and
metabolism are unknown; however, considering the effects of the
previous alfaxalone-alfadolone formulation in both cats and humans,
a dose-dependent decrease in cerebral blood ﬂow (CBF) and cere-
bral metabolic rate of oxygen (CMRO2) is most likely to occur after
the administration of alfaxalone (Baldy-Moulinier et al., 1975; Sari
et al., 1976; Rasmussen et al., 1978; Bendtsen et al., 1985). When
anaesthesia was maintained via a CRI of CT 1341 in cats (and ar-
terial partial-pressure of CO2 was kept constant) a dose-dependent
decrease in CBF and intracranial pressure (ICP) was reported, as well
as concurrent cerebral vasoconstriction (Baldy-Moulinier and
Besset-Lehmann, 1975).
Alfaxalone is thought to exert its effects on CBF primarily via its
depressant effect on intracellular neuronal metabolism, which leads
to metabolically controlled secondary vasoconstriction and a cor-
responding decrease in CBF (Rasmussen et al., 1978). The inﬂuence
of alfaxalone on ICP, cerebral haemodynamics and metabolism
supports the evaluation of the application of this drug for
neuroanaesthesia (Warne et al., 2014).
Neuromuscular effects
Cats anaesthetised with alfaxalone-HPCD maintain a more cen-
trally positioned eye at the depth of anaesthesia appropriate for
orotracheal intubation than those anaesthetised with propofol
(Herbert and Murison, 2013). These results suggest that eye posi-
tion is unlikely to be a reliable indicator of anaesthetic depth
during induction in cats anaesthetised with alfaxalone-HPCD and,
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as such, greater signiﬁcance should be given to other variables,
such as muscle tone, jaw tone, the presence or absence of reﬂexes
(pedal withdrawal, palpebral, corneal, gag, swallow and cough)
and reaction to noxious stimuli.
A study comparing three anaesthetic induction protocols
(alfaxalone-HPCD,midazolam and ketamine, propofol) used to assess
laryngeal function in cats (n = 35) found that alfaxalone-HPCD was
the only protocol in which arytenoid cartilage motion was main-
tained in all cats evaluated (Nelissen et al., 2012). There was no
signiﬁcant difference in the area of the rima glottides in cats
anaesthetised with alfaxalone compared with other protocols
(Nelissen et al., 2012).
The CT 1341 co-formulation reduces lower oesophageal sphinc-
ter pressure without a parallel fall in gastric pressure, and thus may
increase the risk of gastro-oesophageal reﬂux during induction of
anaesthesia in cats (Hashim and Waterman, 1991). However, this
effect may have been speciﬁc to the formulation and has not been
evaluated with alfaxalone-HPCD.
Hepatic and renal effects
No adverse hepatic or renal effects have been associated with
alfaxalone-HPCD anaesthesia in the cat. Alfaxalone is metabolised
in vitro by feline and canine hepatocytes through both phase I (cy-
tochrome P450 dependent metabolites) and phase II (glucuronide
and sulphate conjugation dependent) enzymatic systems (Fig. 1)
(Warne, 2013). Cats and dogs both formed the same ﬁve phase I
alfaxalonemetabolites (allopregnatrione, 3β-alfaxalone, 20-hydroxy-
3β-alfaxalone, 20-hydroxyalfaxalone and 2α-hydroxyalfaxalone)
(Warne, 2013). The phase II metabolites observed were alfaxalone
glucuronide (dog and cat), 20-hydroxyalfaxalone sulphate (dog and
cat), 3β-alfaxalone sulphate (cat only) and 2α-hydroxyalfaxalone
glucuronide (dog only) (Warne, 2013). The major alfaxalone con-
jugates in the cat were 20-hydroxyalfaxalone sulphate and alfaxalone
glucuronide, while in the dog the predominant conjugate was
alfaxalone glucuronide (Warne, 2013).
Haematological and blood biochemistry
No changes in haematology or blood biochemistry have been as-
sociatedwith alfaxalone-HPCD anaesthesia in the cat (Whittem et al.,
2008).
Analgesia
Murison and Taboada (2010) found no beneﬁcial analgesic effect
of alfaxalone-HPCD compared with propofol. Previous studies have
shown that CT 1341 exhibits a direct depressive action on sensory
synapses in dorsal horn neurones of the feline spinal cord, thereby
imparting an analgesic effect (Le Bars et al., 1976). These
antinociceptive effects were subsequently attributed to the inter-
action of the alfadolone component of the CT 1341 co-formulation
and its action at GABAA receptors in the spinal cord (Harrison et al.,
1987a, 1987b; Mistry and Cottrell, 1990; Nadeson and Goodchild,
2000). This was further supported by recent murine studies, which
found that alfadolone caused antinociceptive effects with no signs
of sedation, while alfaxalone caused sedation and anaesthesia, with
no signs of antinociception (Winter et al., 2003).
Endocrine effects
The endocrine effects of alfaxalone-HPCD have not been inves-
tigated; however, CT 1341 anaesthesia does not affect testosterone
levels in male domestic cats and cheetahs, in contrast to thiopen-
tone and ketamine anaesthesia, which have been reported to reduce
testosterone levels in cats (Wildt et al., 1984; Johnstone and Bancroft,
1988). It is thought that alfaxalone is highly speciﬁc for the GABAA
Fig. 1. Comparison of propofol and alfaxalone hepatic metabolism pathways in the cat.
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receptor complex and does not interact with any of the classical cy-
tosolic ho rmonal steroid receptors (Visser et al., 2002).
Clinical application of alaxalone
Alfaxalone-HPCD for sedation and induction of anaesthesia
Administration of alfaxalone-HPCD by the perivascular or IM
routes does not cause tissue irritation (Heit et al., 2004). Alfaxalone-
HPCD can be used as an effective IM or SC sedative or premedication
agent in cats at 2–3mg/kg, alone or in combination with other hyp-
notic or analgesic agents (Ramoo et al., 2013). The peak sedative
effect occurs approximately 30–45 min after SC administration
(Ramoo et al., 2013). Intramuscular administration of alfaxalone-
HPCD provides induction of anaesthesia with stable cardiovascular
and respiratory effects; however, this route is not recommended due
to the large volume required (i.e. 10 mg/kg equating to 1mL/kg IM)
and poor, prolonged recoveries with excitement, ataxia and hyper-
reactivity (Grubb et al., 2013).
Anaesthetic premedicationwithmedetomidine (20 μg/kg IM) plus
morphine (0.3 mg/kg IM) reduces the alfaxalone-HPCD dose re-
quirement for induction of anaesthesia (1.7mg/kg IV) comparedwith
the labelled dose for induction of anaesthesia in cats (5 mg/kg IV)
(Beths et al., 2014). In another study, the premedication combina-
tion acepromazine (0.03mg/kg SC) plus butorphanol (0.3 mg/kg SC)
has also been shown to reduce the alfaxalone-HPCD dose require-
ment for induction of anaesthesia from 4.2 mg/kg IV (without
premedication) to 3.4 mg/kg IV (with premedication). Premedica-
tion also improved the quality of recovery after alfaxalone-isoﬂurane
anaesthesia (Zaki et al., 2009). The uses of a 0.5% W/V rather than
a 1.0% W/V concentration of alfaxalone-HPCD has also been shown
to further reduce the total dose required to achieve intubation to
1.9 mg/kg when combined with acepromazine/butorphanol pre-
medication (Zaki et al., 2009). Laboratory testing performed by the
manufacturer indicates that dilution in 0.9% saline does not result
in degradation of alfaxalone-HPCD (S. Cumming, personal
communication).
No substantial differences have been found between alfaxalone-
HPCD and propofol with respect to the quality of induction and
recovery; however, cats induced with alfaxalone-HPCD exhibit a
greater incidence of paddling and trembling during the recovery
period (Mathis et al., 2012).
Alfaxalone-HPCD for maintenance of anaesthesia in the cat
Alfaxalone-HPCD total intravenous anaesthesia (TIVA) is effec-
tive for neutering surgery in feral and domestic cats at a median
rate of 180 (range 60–250) μg/kg/min IV following 20 μg/kg IM
medetomidine and 0.3 mg/kg IM morphine premedication and
alfaxalone-HPCD IV induction (Beths et al., 2014). Alfaxalone-
HPCD TIVA has also been used successfully for neutering procedures
in kittens less than 12 weeks of age, with no reported side-effects
(O’Hagan et al., 2012). Alfaxalone-HPCD based TIVA has been re-
ported for prolonged anaesthetic maintenance (450 min) of a 14-
year-old male domestic cat undergoing exploratory sternotomy and
diaphragmatic hernia repair (Vettorato, 2013). The median infu-
sion rate of alfaxalone-HPCD was 79 (range 24–121) μg/kg/min;
adjunctive perioperative analgesia consisted of methadone 0.2 mg/
kg IM (prior to anaesthesia) and remifentanil 0.3–0.45 μg/kg/min
IV throughout the procedure (Vettorato, 2013). Cardiovascular sta-
bility and a relatively short and smooth recovery were reported, with
spontaneous ventilation and tracheal extubation occurring 30 and
60 min after alfaxalone suspension, respectively (Vettorato, 2013).
Alfaxalone-HPCD appears to be a good alternative to propofol for
maintenance of anaesthesia.
Comparison of alfaxalone-HPCD and propofol for multiple or
prolonged anaesthesia in the cat
Beths (2008) found that propofol elimination in domestic cats
is almost exclusively via phase II hepatic metabolism, involving both
glucuronide and sulphate conjugation pathways (see Appendix A:
Supplementary Fig. S1). Delayed recoveries seen in cats following
prolonged propofol anaesthesia (Pascoe et al., 2006) may be attrib-
uted to the relative deﬁciency of glucuronidation in cats (Fig. 1). This
deﬁciency means there is a greater reliance on the slower and more
easily saturated sulphate conjugation pathway (Jordan and Woolf,
1987). The relative deﬁciency of glucuronidation in cats explains
this species sensitivity to phenolic compounds (e.g. paracetamol/
acetaminophen) (Court and Greenblatt, 2000) and can explain the
lower propofol hepatic clearance (8.6 mL/kg/min) compared with
alfaxalone (25.1 mL/kg/min) (Whittem et al., 2008; Bester, 2009).
The high alfaxalone clearance is also suggestive of hepatic blood ﬂow
dependence for metabolism and possible extrahepatic metabo-
lism (Whittem et al., 2008).
Nonlinear pharmacokinetics have been described when consec-
utive maintenance doses of alfaxalone-HPCD (2mg/kg every 7min)
were administered to healthy cats (Whittem et al., 2008). In the pres-
ence of hepatic disease, the pharmacokinetics of alfaxalone might
change and prolonged infusion might result in accumulation. Few
studies evaluating prolonged alfaxalone-HPCD infusion in the cat
exist in the literature; however a recent case report described main-
tenance of alfaxalone-HPCD anaesthesia in a 14-year-old male
neutered cat for 7.5 h (Vettorato, 2013). Anaesthesia was
cardiovascularly stable throughout and recovery was smooth. Spon-
taneous ventilation and tracheal extubation were recorded 30 and
60 min after alfaxalone-HPCD suspension, respectively.
‘Shelf life’ of alfaxalone-HPCD
Alfaxalone in HPBC does not support log-phase growth of several
bacterial genera (Bar and Ulitzur, 1994); however, nor does it elim-
inate contamination in the alfaxalone formulation (Strachan et al.,
2008). Shelf life is determined by the need for both chemical and
microbiological (broached vial) stability. Although alfaxalone in HPBC
is stable chemically, restrictions in shelf-life exist because the for-
mulation does not contain a microbiocidal preservative and does
not kill bacteria. Different countries set different criteria for broached
vial stability after microbial contamination. In the UK, labelled rec-
ommendations are that any solution remaining in the vial following
withdrawal of the required dose should be discarded. In Australia
and New Zealand, the labelled recommendations state that the con-
tents of broached vials should preferably be used within 24 h, but
may be stored if necessary at 4 °C for up to 7 days, provided con-
tamination is avoided. In North America, the manufacturer advises
that any unused product should be discarded within 6 h.
Conclusions
Alfaxalone-HPCD is an effective CNS depressant agent, which has
demonstrated minimal impact on the cardiovascular and respira-
tory system in healthy cats. Taking into consideration the very low
incidence of adverse drug related events reported, the newest for-
mulation of alfaxalone provides a good alternative to the existing
intravenous anaesthetic options for healthy cats, although further
work is required to fully understand the pharmacology in this species.
On the basis of known pharmacological properties, and clinical and
experimental reports, alfaxalone-HPCD could be suitable for TIVA,
although further in vivo studies are needed to conﬁrm its applica-
tion for multiple or prolonged anaesthesia in cats.
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